Shares of MedaSorb Technologies Corporation (OTC:MSBT) continued to run on Wednesday, closing at forty three cents, another thirty four percent to the upside. Wednesday's close makes the stock a near triple over the past five trading days and a seven-bagger over the past few months.

Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) traded down by nearly seven percent on Wednesday to close the day at $4.53 - a price that I still consider a good one to buy for those with a long term outlook.

The recently approved Onsolis is either about to launch, or already has launched - according to recent press releases - and as sales royalties start to roll in, BDSI should start trading to the upside.

I like BDSI as a long term growth pick, now that the company has an approved drug on the market, but I also see some short to mid term benefits based on the potential of Meda to register some immediate sales numbers.

I say 'buy the dips' with this one.

Disclosure: Long MSBT, BDSI
Visit Vinny's Blog VFC's Stock House

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

---

Add this page to your favorite Social Bookmarking websites